Background:
COVID-19 MESHD is a new
infectious disease MESHD with severe disease course and high mortality in some groups. Blood tests on admission to the hospital can be useful for stratification of patients and timely correction. Our study investigated the clinical features of
COVID-19 MESHD patients in Latvia and differences in blood tests in groups with different disease severity. Methods: The retrospective study included 100 patients hospitalized in Riga East Clinical University Hospital in Spring 2020. The severity of the disease course was classified by the presence of
pneumonia MESHD and its combination with
respiratory failure MESHD. We have assessed blood cells' count, hemoglobin, hematocrit, erythrocyte sedimentation rate (ESR),
C-reactive protein HGNC (
CRP HGNC),
alanine aminotransferase HGNC, lactate dehydrogenase (LDH), troponin T, electrolytes, creatinine, glomerular filtration rate (GFR), D-dimer, prothrombin time, prothrombin index, oxygen saturation, and temperature on admission to the hospital. Results: Patients were from 18 to 99, 57% males. Comorbidities were found in 74% of patients. The mild, moderate, and severe groups included 35, 44, and 16 patients, respectively. In the severe group, the mortality rate was 50%. The progression to severe
COVID-19 MESHD was associated positively with temperature, ESR,
CRP HGNC, creatinine, LDH, and troponin T and negatively associated with oxygen saturation, eosinophils, and GFR on admission to the hospital. Conclusions:
COVID-19 MESHD severity associates with lower renal function and a higher level of
inflammation MESHD and tissue damage. Eosinophils,
CRP HGNC, ESR, LDH, troponin T, creatinine, and GFR are blood indicators for monitoring patients' condition.